Andrew J. Armstrong, MD, Details PSMA-PET Scan Parameters Indicating Better Survival Outcomes With 177Lu-PSMA-617 in mCRPC
Data from a substudy of the phase 3 VISION trial presented at 2022 ASCO Annual Meeting showed that higher standard mean uptake value by PSMA-PET is strongly associated with outcomes for patients with metastatic castration-resistant prostate cancer.
Andrew Armstrong, MD, MSc, Discusses Key Findings From ARCHES in mHSPC at 2021 ESMO
CancerNetwork® sat down with Andrew Armstrong, MD, MSc, at the 2021 European Society for Medical Oncology Congress to talk about overall survival results found the phase 3 ARCHES study.
Andrew Armstrong, MD, MSc, Discusses Survival Data in mHSPC From ARCHES Trial at 2021 ESMO
Andrew Armstrong, MD, MSc, spoke about key findings, patient crossover, and takeaways from the ARCHES trial for metastatic hormone-sensitive prostate cancer.
AR-V7 Key in Tx of mCRPC
In this video, Dr. Andrew Armstrong explains why AR-V7–positive men rarely benefit from abiraterone or enzalutamide, and advises on AR-V7 testing as a clinical tool.
2 Commerce Drive Cranbury, NJ 08512